| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1965802 | Clinica Chimica Acta | 2013 | 6 Pages |
BackgroundFucosylated haptoglobin (Fuc-Hpt) is a novel cancer biomarker in a variety of pathological conditions. We previously found that the level of Fuc-Hpt is increased in the sera of patients with pancreatic cancer, and established a lectin antibody ELISA using Aleuria aurantia lectin, which specifically binds to fucosylated residues on oligosaccharides.MethodsTo apply this assay system to the clinical detection of several diseases, several assay conditions such as serum dilutions and inhibitory factors were investigated. The Fuc-Hpt kit was available for 25–625 fold serum dilution.ResultsWhile the values of Fuc-Hpt assay using sera and plasma were different, they showed positive correlation. The addition of bilirubin and formagine did not influence on Fuc-Hpt assay, but hemoglobin inhibited this assay in a dose-dependent manner.ConclusionsWe reevaluated this lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions in this study.
► We reevaluated a Fuc-Hpt ELSA kit for its applicability to clinical diagnoses. ► The assayed serum Fuc-Hpt levels were significantly higher than those in plasma. ► 25- to 625-fold dilutions of sera could be used with this ELISA kit. ► Contamination by hemoglobin decreased the measured Fuc-Hpt level. ► Our Fuc-Hpt ELISA kit should prove useful in various clinical applications.
